Pharmaceutical intelligence for competing pharma companies with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Recent signals(2)

RegulatoryJuly 25, 2026

Sunny Pharmtech Issues Recall of Cyclophosphamide Injection Due to Contamination

Sunny Pharmtech is recalling Cyclophosphamide for Injection due to contamination with particulate matter identified as steel.

RegulatoryJuly 23, 2026

FDA Approval Update for Norethindrone Acetate and Ethinyl Estradiol

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for a combination product containing Norethindrone Acetate and Ethinyl Estradiol.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(2)

Regulatory

July 25, 2026

Sunny Pharmtech Issues Recall of Cyclophosphamide Injection Due to Contamination

Sunny Pharmtech is recalling Cyclophosphamide for Injection due to contamination with particulate matter identified as steel.

RegulatoryJuly 23, 2026

FDA Approval Update for Norethindrone Acetate and Ethinyl Estradiol

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for a combination product containing Norethindrone Acetate and Ethinyl Estradiol.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Sunny →

Xiromed →

Therapeutic areas

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.